Paratek Pharmaceuticals Inc.

NASDAQ:PRTK   3:59:38 PM EDT
7.29
+0.28 (+3.99%)
Products

Paratek Pharmaceuticals Announces FDA Approval Of Nuzyra (Omadacycline) Oral Only Dosing Regimen For The Treatment Of Community-Acquired Bacterial Pneumonia (Cabp)

Published: 06/01/2021 11:56 GMT
Paratek Pharmaceuticals Inc. (PRTK) - Paratek Pharmaceuticals Announces FDA Approval of Nuzyra® (omadacycline) Oral Only Dosing Regimen for the Treatment of Community-acquired Bacterial Pneumonia (cabp).